Категории

Challenges and Opportunities in HIV Science

Опубликовано: 16 Июль 2026
на канале: IAS Conference on HIV Science
1,612
9

MOSS01: Challenges and Opportunities in HIV Science. Marijke Wijnroks. Agnes Buzyn. Presented at the 9th IAS Conference on HIV Science (IAS 2017). www.ias2017.org

play_arrow
125
4

Tesis Yönetimi Günü Kutlu Olsun!

Tesis Yönetimi Günü Kutlu Olsun!
play_arrow
834
1

PALFINGER PK16000

PALFINGER PK16000
play_arrow
1,589
17

How Fasting Can Reduce Movement Disorder and Parkinson’s Symptoms

How Fasting Can Reduce Movement Disorder and Parkinson’s Symptoms
play_arrow
51
3

Pokemon Sword & Shield Game Review

Pokemon Sword & Shield Game Review
play_arrow
95
0

How to clone daul what's app & wechat | how to daul whatsapp on Android phone

How to clone daul what's app & wechat | how to daul whatsapp on Android phone
play_arrow
1,056
17

Wirtschaftsprivatrecht (2)

Wirtschaftsprivatrecht (2)
play_arrow
17,597
173

*FE* Free Admin Tools Giver Script Pastebin | Hydrogen • Fluxus Mobile & Pc

*FE* Free Admin Tools Giver Script Pastebin | Hydrogen • Fluxus Mobile & Pc
play_arrow
737
22

САМЫЕ ЛУЧШИЕ игры про РОССИЮ!!!

САМЫЕ ЛУЧШИЕ игры про РОССИЮ!!!
Похожие видео
play_arrow
The Mexico City story: Proud hosts of the 10th IAS Conference on HIV Science (IAS 2019)

The Mexico City story: Proud hosts of the 10th IAS Conference on HIV Science (IAS 2019)
play_arrow
On-demand Oral TDF/FTC for PrEP: Is It an Option?

On-demand Oral TDF/FTC for PrEP: Is It an Option?
play_arrow
Challenges and Opportunities in HIV Science

Challenges and Opportunities in HIV Science
play_arrow
Welcome to Paris - IAS 2017

Welcome to Paris - IAS 2017
play_arrow
TUAB0102 - Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir ...

TUAB0102 - Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir ...
play_arrow
TUAB0101 - Atazanavir/ritonavir 200/100 mg is non-inferior to atazanavir/ritonavir 300/100 mg ...

TUAB0101 - Atazanavir/ritonavir 200/100 mg is non-inferior to atazanavir/ritonavir 300/100 mg ...
play_arrow
Primary HIV Infection and Early Treatment

Primary HIV Infection and Early Treatment
play_arrow
Broadly Neutralizing Antibodies against HIV

Broadly Neutralizing Antibodies against HIV
play_arrow
Antiretroviral Therapy - ART: Season One

Antiretroviral Therapy - ART: Season One
play_arrow
Plenary Session

Plenary Session
play_arrow
IAS 2017 Rapporteur and Closing Session

IAS 2017 Rapporteur and Closing Session
play_arrow
Antiretroviral Therapy - ART: Season Two

Antiretroviral Therapy - ART: Season Two